Regorafenib combined with irinotecan as second-line treatment in metastatic gastro-oesophageal adenocarcinomas: results of PRODIGE 58-UCGI35-REGIRI Unicancer randomised phase II study
瑞戈非尼联合伊立替康作为转移性胃食管腺癌二线治疗：PRODIGE 58-UCGI35-REGIRI Unicancer 随机 II 期研究结果
期刊:ESMO Open
影响因子:8.3
doi:10.1016/j.esmoop.2025.105096
Samalin, E; Evesque, L; Turpin, A; De La Fouchardiere, C; Khemissa-Akouz, F; Bouché, O; Muller, M; Dermeche, S; Botsen, D; Tougeron, D; Zaanan, A; Ben Abdelghani, M; Guardiola, E; Dubreuil, O; Le Brun Ly, V; Hennequin, A; Watson, S; Sefrioui, D; Lecomte, T; De Sousa Carvalho, N; Hulin, A; Crapez, E; Castan, F; Senellart, H
